Literature DB >> 20151345

Pathophysiology and diagnosis of dyspnea in patients with advanced cancer.

Gudrun Pohl1, Jan Gaertner.   

Abstract

The reported prevalence of dyspnea in patients with various cancers ranges from 19% to 64%. For optimal clinical management of dyspnea in cancer patients, accurate diagnosis of the underlying cause and thorough understanding of the pathomechanisms of dyspnea seems mandatory. The clinical approach to a patient with advanced cancer and dyspnea should include adequate history taking, physical examination, and selected diagnostic investigations. These should be performed immediately to enable quick treatment decisions. In addition, self assessment of the intensity of dyspnea by the patient may help to assess patient's needs as soon as possible.

Entities:  

Mesh：

Year:  2009        PMID： 20151345     DOI： 10.1007/s10354-009-0725-1

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  29 in total

1.  Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments.

Authors:  M T Claessens; J Lynn; Z Zhong; N A Desbiens; R S Phillips; A W Wu; F E Harrell; A F Connors
Journal:  J Am Geriatr Soc       Date:  2000-05       Impact factor: 5.562

Review 2.  Advancing the science of symptom management.

Authors:  M Dodd; S Janson; N Facione; J Faucett; E S Froelicher; J Humphreys; K Lee; C Miaskowski; K Puntillo; S Rankin; D Taylor
Journal:  J Adv Nurs       Date:  2001-03       Impact factor: 3.187

Review 3.  Assessment of dyspnea in advanced cancer patients.

Authors:  I Mancini; J J Body
Journal:  Support Care Cancer       Date:  1999-07       Impact factor: 3.603

4.  Dyspnea in cancer patients: prevalence and associated factors.

Authors:  D J Dudgeon; L Kristjanson; J A Sloan; M Lertzman; K Clement
Journal:  J Pain Symptom Manage       Date:  2001-02       Impact factor: 3.612

5.  The course of symptom frequency and intensity in advanced cancer patients followed at home.

Authors:  S Mercadante; A Casuccio; F Fulfaro
Journal:  J Pain Symptom Manage       Date:  2000-08       Impact factor: 3.612

6.  Symptom prevalence in the last week of life.

Authors:  C Conill; E Verger; I Henríquez; N Saiz; M Espier; F Lugo; A Garrigos
Journal:  J Pain Symptom Manage       Date:  1997-12       Impact factor: 3.612

7.  The frequency and correlates of dyspnea in patients with advanced cancer.

Authors:  E Bruera; B Schmitz; J Pither; C M Neumann; J Hanson
Journal:  J Pain Symptom Manage       Date:  2000-05       Impact factor: 3.612

8.  Psychophysical bases of perceived exertion.

Authors:  G A Borg
Journal:  Med Sci Sports Exerc       Date:  1982       Impact factor: 5.411

9.  Dyspnea in terminally ill cancer patients.

Authors:  D B Reuben; V Mor
Journal:  Chest       Date:  1986-02       Impact factor: 9.410

10.  Common symptoms in patients with advanced cancer.

Authors:  E B Curtis; R Krech; T D Walsh
Journal:  J Palliat Care       Date:  1991       Impact factor: 2.250
View more
  2 in total

Review 1.  Symptomatic treatment of dyspnea in advanced cancer patients : A narrative review of the current literature.

Authors:  Matthäus Strieder; Martin Pecherstorfer; Gudrun Kreye
Journal:  Wien Med Wochenschr       Date:  2017-09-18

2.  Pretreatment quality of life as a prognostic factor for early survival and functional outcomes in patients with head and neck cancer.

Authors:  Chan Joo Yang; Jong-Lyel Roh; Min-Ju Kim; Sang-wook Lee; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Qual Life Res       Date:  2015-07-09       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.